stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Revenue growth
AstraZeneca PLC's revenue growth over the twelve months to 30 September 2026 was 7.32%, down 1.3 percentage points from fiscal 2025 (8.63%). Over the past ten years it has ranged from −6.93% (fiscal 2015) to 40.6% (fiscal 2021); the current reading is higher than 55% of that period. That is above the Drug Manufacturers General industry median of 6.72% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 8.63% | (9.40) |
| FY2024 | 18.0% | 14.74 |
| FY2023 | 3.29% | (15.24) |
| FY2022 | 18.5% | (22.05) |
| FY2021 | 40.6% | 31.42 |
| FY2020 | 9.16% | (1.22) |
| FY2019 | 10.4% | 12.05 |
| FY2018 | −1.67% | 0.66 |
| FY2017 | −2.33% | 4.57 |
| FY2016 | −6.90% | 0.03 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 6.70% | 0.29 |
| Jun 2026 | 6.41% | (6.10) |
| Mar 2026 | 12.5% | 8.40 |
| Dec 2025 | 4.11% | (7.88) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NVO Novo Nordisk A/S compare | 13.2% |
| ABBV AbbVie Inc. compare | 10.7% |
| AMGN Amgen Inc. compare | 8.15% |
| AZN AstraZeneca PLC | 7.32% |
| GILD Gilead Sciences, Inc. compare | 6.54% |
| MRK Merck & Co., Inc. compare | 4.89% |
| BMY Bristol Myers Squibb Company compare | 4.16% |
| NVS Novartis AG compare | 1.76% |
| PFE Pfizer Inc. compare | 1.34% |
| Drug Manufacturers General industry median | 6.72% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement